Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
Gastric Cancer
DRUG: Veliparib
Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors, Screening to follow up visit
To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens., Screening to follow up visit
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.